Fig. 4: In vivo performance of CAR T cells with or without IFP constructs.
From: Rational design of PD-1-CD28 immunostimulatory fusion proteins for CAR T cell therapy
a Experimental layout of the Nalm-6 xenograft tumour model. Mice were implanted with 5 × 104 PD-L1+ Luc+ Nalm-6 tumour cells intravenously and three days after treated with a single injection of 107 Untransduced, CAR-, PTM-, CAR- and PTM-, CTM + 12EC-, CAR- and CTM + 12EC-, CTMΔ12EC-, CAR- and CTMΔ12EC-transduced T cells (n = 5 mice per group, representative of 2 independent experiments with different donors). Mice were imaged for luminescence signals every four days. b Percentage survival readout. c Weight change in % of mice from different treatment groups. The weight for each day is normalised to the initial value on day 0. d Representative in vivo imaging data displaying luminescent signal in radiance for all individual mice from treatment day onwards. e IFN-γ levels in the serum of mice treated with anti-CD19 CAR as control and in combination with IFPs. Blood was collected on day five after ACT. Differences between relevant groups for (b) were calculated using Log-rank (Mantel-Cox) test. P values for pertinent groups of (c) are based on two-way ANOVA followed by Dunnett’s multiple comparisons tests. P values for (e) are based on a two-tailed unpaired t-test.
